Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

被引：0

作者：

Eulalia Jimenez

Carol Astbury

Muna Albayaty

Ulrika Wählby-Hamrén

Beatriz Seoane

Cristina Villarroel

Helena Pujol

Maria Jesus Bermejo

Ajay Aggarwal

Ioannis Psallidas

机构：

[1] Clinical Pharmacology and Quantitative Pharmacology,

[2] Clinical Pharmacology & Safety Sciences,undefined

[3] R&D,undefined

[4] AstraZeneca,undefined

[5] Research and Early Development,undefined

[6] Respiratory,undefined

[7] Inflammation and Autoimmune,undefined

[8] BioPharmaceuticals R&D,undefined

[9] AstraZeneca,undefined

[10] Early Phase Clinical Unit,undefined

[11] PAREXEL International GmbH,undefined

[12] Clinical Pharmacology and Quantitative Pharmacology,undefined

[13] Clinical Pharmacology & Safety Sciences,undefined

[14] R&D,undefined

[15] AstraZeneca,undefined

[16] Biometrics and Information Sciences,undefined

[17] Late-Stage Development,undefined

[18] BioPharmaceuticals R&D,undefined

[19] AstraZeneca,undefined

[20] Late-Stage Development,undefined

[21] BioPharmaceuticals R&D,undefined

[22] AstraZeneca,undefined

[23] Patient Safety,undefined

[24] Chief Medical Office,undefined

[25] R&D,undefined

[26] AstraZeneca,undefined

[27] Research and Early Development,undefined

[28] Respiratory,undefined

[29] Inflammation and Autoimmune,undefined

[30] BioPharmaceuticals R&D,undefined

[31] AstraZeneca,undefined

来源：

Respiratory Research | / 21卷

关键词：

Bronchodilator; Asthma; MABA, dual-pharmacology muscarinic receptor antagonist β; -adrenoceptor agonist; Safety; Pharmacokinetics;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 32 条

[1]

Kew KM(2016)Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma Cochrane Database Syst Rev 1 CD011721-1207

[2]

Dahri K(2012)Tiotropium in asthma poorly controlled with standard combination therapy N Engl J Med 367 1198-887

[3]

Kerstjens HA(2015)Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study PLoS One 10 e0124109-456

[4]

Engel M(2013)The MABA approach: a new option to improve bronchodilator therapy Eur Respir J 42 885-838

[5]

Dahl R(2014)Considerations for new dual-acting bronchodilator treatments for chronic obstructive pulmonary disease Expert Opin Investig Drugs 23 453-299

[6]

Ohta K(2008)Patient adherence in COPD Thorax. 63 831-334

[7]

Ichinose M(2008)Novel long-acting bronchodilators for COPD and asthma Br J Pharmacol 155 291-1605

[8]

Tohda Y(2011)Factors associated with medication adherence in patients with chronic obstructive pulmonary disease Respiration. 82 328-504

[9]

Cazzola M(2011)Dual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary disease Future Med Chem 3 1585-464

[10]

Lopez-Campos JL(2012)Pharmacology and therapeutics of bronchodilators Pharmacol Rev 64 450-undefined

← 1 2 3 4 →